While attention had been focused on whether the company’s shares would rebound following the event, they instead declined steeply. In contrast, Vigencell surged to the daily limit after being selected for an oral presentation at a major global conference, highlighting a stark divergence in market reactions.
Samchundang Pharm stock trend.(Source=MP DOCTOR)
The company had previously announced that it would present key data supporting its oral delivery platform ‘S-PASS’ at an analyst meeting held on April 21. The agenda included pharmacokinetic(PK) data for its oral insulin candidate SCD0503, bioequivalence(BE) data for an oral semaglutide generic, and research results demonstrating the feasibility of oral formulations for antibody drugs such as etanercept and aflibercept.
At the time, a company official stated that the session would “comprehensively present key research data” and “objectively demonstrate the feasibility of oral insulin.”
However, despite heightened anticipation, no official disclosure followed the meeting and no analyst reports were issued, rapidly eroding market expectations. Industry sources noted that this information vacuum contributed to weakening investor confidence and accelerated the stock’s decline.
Interviews with analysts who attended the meeting revealed largely negative assessments of the data presented. The briefing was delivered by an IR executive in the absence of CEO Jeon In seok.
According to attendees, aside from limited PK data related to oral insulin, most of the materials consisted of animal-based experimental results. Notably, the human pharmacokinetic(PK) data from a crossover study widely anticipated by the market was not disclosed.
A crossover study involves administering both a test drug and a reference drug to the same subjects sequentially and directly comparing blood drug concentrations. It is considered the gold standard for demonstrating bioequivalence(BE) in generic drug development.
In Samchundang’s case, this would require comparing its S-PASS-based oral semaglutide formulation with the reference drug Rybelsus under identical conditions, analyzing key PK parameters such as maximum concentration(Cmax), total exposure(AUC), and time to peak concentration(Tmax). Typically, BE is established when the ratios of Cmax and AUC fall within the 80–125% range.
“One of the expectations going into the meeting was to see crossover study data, but that was not presented. Most of what was shown were animal study results,” said one analyst. Industry observers noted that given the central role of crossover studies in BE validation, and the fact that the data presented was largely preclinical, the overall reception of the meeting has been largely dismissive.
◇Vigencell to Deliver Oral Presentation of Phase 2 Cell Therapy Data at ASCO
Meanwhile, Vigencell drew strong investor interest after its pipeline advanced onto the global stage. The company’s stock hit the daily upper limit following the announcement that its cell therapy candidate had been selected for an oral presentation at the American Society of Clinical Oncology(ASCO 2026).
Shares of Vigencell jumped 29.88%(won 1,700) to close at won 7,390 with the rally largely attributed to the ASCO oral presentation selection of its cell therapy candidate ‘VT-EBV-N’.
ASCO, the world’s largest clinical oncology conference, will be held in Chicago from May 29 to June 2. Oral presentations are reserved for a very limited number of abstracts deemed to have high clinical and scientific significance.
“Most abstracts are presented as posters, so being selected for an oral presentation indicates a positive evaluation of the therapy,” a company official said. “Among oral formats, standard oral presentations are considered more significant than rapid oral sessions.”
VT-EBV-N is a cell therapy targeting Epstein-Barr virus(EBV)-related diseases. The presentation will focus on Phase 2 clinical results demonstrating reduced recurrence risk and improved survival outcomes.
The company stated that the therapy has shown meaningful improvements in patient prognosis, particularly in reducing recurrence one of the key factors impacting survival in cancer treatment.
“We believe the stock’s surge reflects the impact of the ASCO oral presentation,” a company official said.
CEO Ki Pyeong-seok added, “Protecting patients from recurrence is the ultimate goal in cancer treatment. VT-EBV-N has demonstrated that potential through clinical data. We aim to leverage the recognition from ASCO to accelerate global partnerships and enhance corporate value, while providing new treatment options for patients.”
